E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018937 |
E.1.2 | Term | Haemophilia A |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective of Part A , Part B To assess the incidence rate of FVIII inhibitors (≥0.6 BU/mL) |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives of Part A and Part B • To evaluate the clinical efficacy of N8 in bleeding prevention in subjects with haemophilia A. • To evaluate the clinical efficacy of N8 when treating bleeds in subjects with haemophilia A. • To evaluate the safety of N8 when used for prevention of bleeding episodes and treatment of mild, moderate, and severe bleeds in subjects with haemophilia A • To assess changes in Patient Reported Outcomes (PROs) from screening to end of trial • Part A only: To describe and compare the PK profile of N8 in the subjects who participated in both this trial and NN7008-3522.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Part C: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding during Surgical Procedures in Subjects with Haemophilia A
Date: 29 Jan 2010 Version: 10
Primary Objective of Part C To assess the incidence rate of FVIII inhibitors (≥0.6 BU/mL)
Secondary Objectives of Part C • To evaluate the efficacy of N8 during surgical procedures in subjects with haemophilia A • To evaluate the haemostatic response to N8 in the post-surgery period for subjects with haemophilia A • To evaluate the safety of N8 when used for prevention and treatment of bleeding during surgical procedures and in the surgery period in subjects with haemophilia A • To assess changes in PROs from pre-surgery to last day of recovery |
|
E.3 | Principal inclusion criteria |
Part A 1. Completion of the phase 1 PK trial NN7008-3522 2. Informed consent obtained prior to any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.) 3. Male subjects with the diagnosis of severe (FVIII≤1%) haemophilia A from age 12 (except for Israel where the age limit will be 18 for the first 10 subjects recruited in the trial ) to 56 years having a weight of 10 to 120 kg. 4. Willing to undergo a bleeding preventative treatment of 75 dose days 5. Non-bleeding state (i.e. no clinical manifestation of active bleed) at the time of administration of trial product for measurement of recovery in relation to administration of the first dose and the PK session 6. Documented history of at least 150 exposure days to any other FVIII products (prevention or treatment of bleeds) (Please refer to section 8.6.2.3) 7. No history of FVIII inhibitors ≥0.6 BU/mL. The inhibitor should be measured regularly for at least the last 8 years or since the first treatment of haemophilia A (Please refer to section 8.6.2.2) 8. No detectable inhibitors to FVIII (≥0.6 BU/mL) (as assessed by a Central Laboratory at the time of screening) 9. Not in use 10. Not in use 11. HIV-1 seronegative or if HIV-1 seropositive, viral load < 400.000 copies/mL and CD4+ lymphocyte count ≥200/μL. Subjects who have completed NN7008-3522 have already met inclusion criteria no 1-3 and 5-11 in NN7008-3522. Part B 1. Informed consent obtained prior to any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject). 2. Male subjects with the diagnosis of severe (FVIII≤1%) haemophilia A from age 12 (except for Israel where the age limit will be 18 for the first 10 subjects recruited in the trial and 18 for all subjects in Croatia) to 65 years having a weight of 10 (20 in Brazil) to 120 kg. 3. Willing to undergo a bleeding preventative treatment of 75 dose days 4. Non-bleeding state (i.e. no clinical manifestation of active bleed) at the time of administration of trial product for measurement of recovery in relation to administration of the first dose (please refer to section 8.2.2) 5. Documented history of at least 150 exposure days to any other FVIII products (prevention or treatment of bleeds) (Please refer to section 8.6.2.3) 6. No prior history of FVIII inhibitors. Documentation should be available for at least the last 8 years (or since treatment with FVIII products started if shorter than 8 years), please refer to Section 8.6.2.2)for required documentation 7. No detectable inhibitors to FVIII (≥0.6 BU/mL) (as assessed by a Central Laboratory at the time of screening) 8. Not in use 9. Not in use 10. HIV-1 seronegative or if HIV-1 seropositive, HIV viral load < 400.000 copies/mL and CD4+ lymphocyte count ≥200/μL. Eligibility Criteria for Part C 1. Undergo major or minor surgical procedures (Please refer to section 8.2.8) 2. Surgical procedure requiring at least 7 days of infusion of N8 post-operatively Subjects will only participate in Part C when they have been included in either Part A or Part B and have received at least one dose of trial product (N8). Subjects can be recruited into part C when at least 5 subjects have each been treated with N8 for a bleeding episode and 80% of these subjects have a response rated excellent or good on the four–point haemostatic response scale for their first bleeding episode. |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria for Part A and Part B 1. Subjects receiving Immune modulating medication or Tolerance Induction (ITI) regimens 2. Factor replacement treatment of a mild or moderate bleeding episode within 3 days prior to first dose (only applicable for subjects in Part B) 3. Factor replacement treatment of a severe bleeding episode within one week prior to first dose (only applicable for subjects in Part B) 4. Known pseudo-tumours 5. Platelet count <50,000 platelets/μL based on medical records and/or based on local laboratory values at trial entry 6. Severe current hepatic dysfunction or severe hepatic disease during the last 12 months 7. ALT > 4 times the upper limit of normal reference range (as defined by central laboratory ranges) (only for subjects in Part A) 8. Febrile illness within 5 days prior to the first trial product administration and PK dosing 9. Current dialysis therapy 10. Creatinine levels 50% above normal level (as defined by central laboratory range) 11. Congenital or acquired coagulation disorders other than haemophilia A 12. Previous arterial thrombotic events (Myocardial Infarction and Intra Cranial Thrombosis) (as defined by medical records). 13. Known or suspected allergy to trial product (N8) or related products 14. Surgery within one month prior to first administration of trial product (catheter, stents, ports, and dental extractions do not count as surgeries, i.e. they will not exclude the subject) 15. Use of Coagulation Factors other than N8: Commercial FVIII concentrates or other FVIII containing products within 48 hours prior to first administration of trial product for recovery assessment. (not applicable for Part A subjects 1-3) 16. Use of Anticoagulants: Heparin, vitamin-K antagonists, and direct thrombin inhibitors one week prior to first administration of trial product 17. Not in use 18. Not in use 19. Use of platelet inhibitors including NSAID one week prior to first administration of trial product (only for subjects in Part A) 20. The receipt of any investigational drug within 30 days prior to administration of trial product except subjects who have completed NN7008-3522 (for Brazil within one year prior to screening for this trial, unless there, in the investigators opinion, is a direct benefit to the research subject) 21. Previous participation in the current trial (defined as withdrawal) or withdrawn subjects from NN7008-3522 after administration of trial product 22. Any disease or condition which, according to the Investigator’s judgement, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome 23. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoint for Part A, Part B and Part C • The incidence rate of Factor VIII inhibitors (≥0.6 BU/mL) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |